To monitor changes in TGF-β signaling-related genes in CTCs throughout the extended clinical course of Atezo+Bev in patients with HCC, we investigated the gene expression of CDKN2B, GRB2, and PIK3R1 in CTCs. The gene discussed is GRB2; the disease is hepatocellular carcinoma.